■ 编者按 今年是"十四五"规划收官之年。中央企业完整准确全面贯彻新发展理念、实现高质量发展，全面提升科 技创新能力、扎实推进布局优化结构调整，深入实施国有企业改革深化提升行动，不断增强核心功能、 提升核心竞争力。肩负国计民生，中央企业的"十四五"成果，最终体现为人民群众的体验感、获得感与 幸福感。即日起，国务院国资委新闻中心联合中国证券报推出"答卷'十四五' 央企惠民生"系列报道，以 百姓生活的"小切口"，折射中央企业改革发展的"大变化"。 ● 本报记者 刘丽靓 傅苏颖 近日，中国电子旗下中电云脑正式发布我国首款国芯非侵入式脑机智能头环，备受市场关注。"头环采 用了国产化的脑电采集芯片，推出一个多月以来，采购意向已接近20万套，其中已签订正式合同的超过 十万套。"中电云脑（天津）科技有限公司总经理程龙龙接受采访时表示。这一成果是中央企业以科技 创新驱动医疗健康产业升级的一个缩影。 从突破脑机接口与微光夜视前沿技术，到构建"息壤"算力平台支撑前沿科研；从推动"智慧医院"驶入偏 远山村，到保障罕见病药品供应与养老服务深入社区……近年，一批中央企业以技术突破为引擎，以民 生需求为导向，持续攻坚医疗健康"新高地"。 ...

Group 1: Suzhou's Economic Landscape - Suzhou is one of the most active cities for private economy in China, focusing on technology development and exploring diverse markets to overcome "involution" challenges [1] - The city has seen significant private investment, with private enterprises accounting for 88.1% of total foreign investment projects and 74.2% of total investment amount [3] Group 2: Company Innovations and Developments - SIBICHI Technology Co., Ltd. specializes in human-computer interaction technology, with applications in smart vehicles and digital offices, and has established joint laboratories with universities for innovation [1] - Beikang Medical Co., Ltd. has developed a pre-implantation genetic testing kit, filling a clinical gap in China's third-generation IVF technology, and aims to enhance domestic industry chain capabilities [2] - Ecovacs Robotics focuses on household service robots and has expanded internationally, with overseas revenue projected to reach 6.8 billion RMB in 2024, accounting for over 40% of total revenue [2] Group 3: Market Performance - Suzhou's private enterprises achieved a total import and export volume of 486.6 billion RMB in the first half of the year, with exports growing by 10.2% year-on-year [3]

Core Insights - The 2025 China International Service Trade Fair (CIFTIS) officially opened on September 10, showcasing over 500 enterprises from Beijing Economic-Technological Development Area (BDA) [1] - BDA aims to leverage the international platform of CIFTIS to demonstrate its innovative practices in building a high-end industrial complex and a new model of productivity [1] Group 1: Technological Innovations - The BDA exhibition featured a digital human named YURI promoting the upcoming 2025 GT World Challenge in Beijing, filling a decade-long gap in international automotive events in the city [2] - The "Modular World" section highlighted innovations in artificial intelligence, including a digital human solution from JIC Technology, which holds the top market share in the industry [2] - VAST showcased AI 3D modeling technology capable of generating high-fidelity 3D content in minutes, while Tsinghua Academy of Fine Arts presented an installation that converts plant signals into melodies [2] Group 2: Commercial Aerospace - The "Rocket Street" section emphasized BDA's advantages in the commercial aerospace sector, housing over 75% of China's commercial rocket companies and achieving significant technological breakthroughs [3] - BDA's "Yizhuang Arrow" has successfully completed multiple launch missions in 2025, with plans for over 40 launches and more than 130 satellites to be placed into orbit this year [3] Group 3: Diverse Industry Representation - Numerous high-tech enterprises from BDA showcased innovative products across various sectors, including healthcare, supply chain services, cultural tourism, financial services, and telecommunications [4] - GE Healthcare and local companies like Tongrentang and Changmugu presented cutting-edge healthcare solutions, including the debut of the PET/CT device Max Elite+ [4] - In the telecommunications sector, companies like Loongson Technology and ZTE highlighted their contributions, with a cloud control platform being a key feature of the exhibition [5] Group 4: Global Engagement - The exhibition runs until September 14, featuring various industry matchmaking and experiential activities, with BDA actively participating to promote its services and manufacturing capabilities globally [5] - A themed investment promotion conference for high-quality development in Yizhuang is scheduled for September 12, aiming to attract global attention and investment [5]

Core Viewpoint - WanDong Medical's stock has shown a significant increase in price and trading volume, indicating positive market sentiment despite a decline in net profit [1][2]. Financial Performance - For the first half of 2025, WanDong Medical reported revenue of 843 million yuan, representing a year-on-year growth of 20.46% [2]. - The company's net profit attributable to shareholders was 51.30 million yuan, which reflects a year-on-year decrease of 39.46% [2]. Stock Performance - As of September 15, WanDong Medical's stock price increased by 24.92% year-to-date, with a recent 5-day increase of 1.08%, a 20-day increase of 5.47%, and a 60-day increase of 9.29% [1]. - The stock was trading at 18.70 yuan per share with a market capitalization of 13.15 billion yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.69% to 26,800, while the average number of circulating shares per person increased by 13.24% to 26,201 shares [2]. - The top ten circulating shareholders include notable entities such as HuaBao ZhongZheng Medical ETF and Hong Kong Central Clearing Limited, with changes in their holdings [3]. Dividend Distribution - Since its A-share listing, WanDong Medical has distributed a total of 769 million yuan in dividends, with 267 million yuan distributed over the past three years [3]. Company Overview - WanDong Medical, established on May 12, 1997, specializes in the research, manufacturing, and sales of imaging medical devices, with 88.18% of its revenue coming from medical device sales [1].

Core Viewpoint - David Medical's stock has experienced fluctuations, with a recent decline despite a year-to-date increase, indicating potential volatility in the market [1][2]. Company Overview - David Medical, established on September 18, 1992, and listed on May 8, 2012, is located in Xiangshan, Ningbo, Zhejiang Province. The company specializes in the research, production, and sales of infant care equipment [2]. - The main revenue sources are: 51.93% from obstetric and pediatric care equipment, 45.88% from minimally invasive surgical instruments, and 2.18% from other products [2]. Stock Performance - Year-to-date, David Medical's stock price has increased by 31.03%. However, it has seen a decline of 3.17% over the last five trading days and 1.61% over the last 20 days. In contrast, the stock rose by 21.36% over the past 60 days [2]. - As of September 15, the stock price was reported at 14.64 CNY per share, with a market capitalization of 4.216 billion CNY [1]. Financial Performance - For the first half of 2025, David Medical reported a revenue of 251 million CNY, a year-on-year decrease of 5.48%. However, the net profit attributable to shareholders increased by 9.57% to 50.9767 million CNY [2]. Shareholder Information - As of August 29, the number of shareholders was 22,400, a decrease of 2.18% from the previous period. The average number of circulating shares per person increased by 2.23% to 6,417 shares [2]. - The company has distributed a total of 342 million CNY in dividends since its A-share listing, with 120 million CNY distributed in the last three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Ling Huo Pei Zhi Mixed Fund (004685) is the fourth largest with 900,000 shares, and Yuan Xin Yong Feng Ju You A (010469) is the fifth largest with 882,000 shares, both being new shareholders [3].

9月15日，澳华内镜盘中下跌2.01%，截至10:01，报48.23元/股，成交1919.84万元，换手率0.29%，总市 值64.95亿元。 资金流向方面，主力资金净流入42.41万元，特大单买入136.65万元，占比7.12%，卖出0.00元，占比 0.00%；大单买入186.18万元，占比9.70%，卖出280.42万元，占比14.61%。 澳华内镜今年以来股价涨20.27%，近5个交易日跌7.52%，近20日跌6.87%，近60日跌0.17%。 资料显示，上海澳华内镜股份有限公司位于上海市闵行区光中路133弄66号，成立日期1994年10月27 日，上市日期2021年11月15日，公司主营业务涉及从事电子内窥镜设备及内窥镜诊疗手术耗材研发、生 产和销售的高新技术企业。主营业务收入构成为：内窥镜设备92.35%，内窥镜诊疗耗材3.71%，内窥镜 维修服务收入3.58%，租赁收入0.35%。 澳华内镜所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：医用耗材、小盘、医疗 器械、养老金概念、专精特新等。 截至6月30日，澳华内镜股东户数3921.00，较上期减少2.51%；人均流通股34344 ...

Company Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, is located in Shanghai and specializes in the research, production, sales, and service of digital X-ray detectors [1] - The company's main revenue sources include detector sales (81.21%), core component sales (7.66%), solution/technical service revenue (5.89%), accessory sales (4.57%), and rental income (0.66%) [1] Financial Performance - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, representing a year-on-year growth of 3.94%, and a net profit attributable to shareholders of 335 million yuan, with an increase of 8.82% year-on-year [2] - The company has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3] Stock Performance - On September 15, Yirui Technology's stock price decreased by 2.05%, trading at 109.20 yuan per share, with a market capitalization of 21.864 billion yuan [1] - The stock has seen a year-to-date increase of 61.60%, a decline of 7.84% over the last five trading days, a slight increase of 1.10% over the last 20 days, and a rise of 24.67% over the last 60 days [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per person, up by 15.02% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF is a new entrant holding 3.926 million shares, while Jingshun Changcheng New Energy Industry Stock A has exited the list [3] Market Position - Yirui Technology operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with concepts such as oral healthcare, specialized and innovative enterprises, mid-cap stocks, margin financing, and share buybacks [1]

国务院副总理丁薛祥和北京市委书记尹力巡视服贸会，在鹰瞳Airdoc AI健康产品展台驻足。 北京卫视《北京新闻》报道： 2025年中国国际服务贸易交易会于9月10号在北京举行。中共中央政治局 常委、国务院副总理丁薛祥出席全球服务贸易峰会并发表主旨讲话。峰会结束后，丁薛祥和尹力一起巡 视服贸会展馆，在与参展单位负责人交流时，丁薛祥说："中国将持续推进高水平对外开放，积极扩大 优质服务进出口，为中外企业提供更多发展机遇，更好满足各国人民美好生活需要。" 丁薛祥副总理和北京市委书记尹力在健康卫生服务展区，听取了国家人工智能应用中试基地（医疗领 域）的汇报。鹰瞳Airdoc作为国家人工智能应用中试基地（医疗领域）的合作生态之一，在本届服贸会 展示了多款AI健康创新产品。 服贸会参会人员体验了鹰瞳Airdoc PBM视力康复仪、鹰瞳Airdoc视网膜慢病风险评估、鹰瞳Airdoc人工 智能抗压能力监测等人工智能健康产品。鹰瞳Airdoc AI健康产品吸引了新华社、CCTV-2财经、央视新 闻客户端、央广网、央视频等多家媒体记者的关注，并获得广泛关注与报道。 鹰瞳科技（Airdoc）AI健康产品在服贸会大放异彩，备受关注 ...

Core Viewpoint - Huakang Clean has shown significant stock performance and financial growth, indicating strong market interest and operational success in the medical purification sector [1][2]. Financial Performance - As of August 29, Huakang Clean achieved a revenue of 835 million yuan for the first half of 2025, representing a year-on-year growth of 50.73% [2]. - The net profit attributable to shareholders for the same period was 18.68 million yuan, marking a substantial increase of 273.48% year-on-year [2]. Stock Performance - The stock price of Huakang Clean increased by 69.49% year-to-date, with a recent rise of 3.26% over the last five trading days [1]. - The stock reached a price of 34.17 yuan per share, with a market capitalization of 3.682 billion yuan [1]. Shareholder Information - As of August 29, the number of shareholders increased to 11,200, reflecting a 3.20% rise from the previous period [2]. - The average number of circulating shares per shareholder decreased by 3.10% to 6,465 shares [2]. Dividend Distribution - Huakang Clean has distributed a total of 40.02 million yuan in dividends since its A-share listing, with 29.46 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Anxin Medical Health Stock A and Nuoan Multi-Strategy Mixed A, both of which are new entrants among the top ten circulating shareholders [3].

Summary of Medical Equipment Industry Conference Call Industry Overview - The medical equipment industry experienced a revenue decline of 7.3% year-on-year in the first half of 2025, with Q2 revenue dropping by 9% [2] - The overall gross margin for the sector was 50.5%, with a slight decrease in Q2 compared to the previous year [2] - Domestic tender procurement is gradually recovering, with a 51% year-on-year increase from January to August [2][3] - The competitive landscape has led to extended revenue recognition cycles, resulting in a significant drop in actual revenue corresponding to last year's tenders [2] Company Performance Mindray Medical - Domestic revenue decreased by 30%, while overseas revenue grew by 5.39% [4] - The life information and support product line saw a 32% decline in revenue [5] - The company is expected to see recovery in Q3 due to increased market share in consumables and IVD products [6][8] United Imaging - Overseas revenue increased by 22.5%, accounting for nearly 20% of total revenue [4] - Domestic market growth was 11%, with several new products approved [5] - MRI equipment revenue grew by 16.81%, while CT equipment sales declined due to high procurement during the pandemic [3][14] KAILI Medical - Overall revenue faced pressure, with a 9% decline in domestic revenue and a 10% drop in gross margin [19] - Soft endoscope revenue grew over 20%, primarily due to breakthroughs in distribution channels [4][19] - The company is focusing on R&D in ultrasound and minimally invasive surgery [20] BGI Genomics - Revenue decreased by 8%, with a net loss reported [21] - Domestic sequencing business saw a double-digit decline, but sales volume of sequencing instruments increased [21] - The inclusion of Illumina on the unreliable entity list by the Chinese Ministry of Commerce is expected to boost BGI's market share [21] Wandong Medical - Achieved a 20% overall revenue growth, benefiting from increased sales of DRCT products and procurement expansion [4][22] - The company is pursuing a dual-driven strategy in domestic and overseas markets, with good growth prospects in Southeast Asia, South America, and Africa [22] Market Trends and Future Outlook - The medical imaging equipment tendering process is recovering, with a 51% year-on-year increase from January to August [5] - The overall trend for international expansion is positive, although short-term demand fluctuations are expected due to complex international conditions [6] - The second half of 2025 is anticipated to show significant improvement due to industry restructuring and the initiation of equipment upgrade projects [7] - Increased investment in consumables is expected to optimize business structures and improve revenue proportions [7] Key Insights - The medical equipment sector is facing challenges due to competitive pressures and extended revenue recognition cycles, but recovery is anticipated in the latter half of 2025 [2][7] - Companies are adapting by focusing on international markets and enhancing product offerings to mitigate domestic market pressures [6][8] - New technologies, such as AI and advanced imaging solutions, are becoming focal points for R&D and market competitiveness [18][20]